About
About Nantong Jinghua Pharmaceutical Co., Ltd
Jinghua Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. It also provides Jidesheng antivenomous tablets, Nantong Wang's baby health pill, Ningning ZhengChaihu granules, Dachaihu granules, Gubenkechuan tablets, dizziness treatment syrup, and Jinqiaomai tablets; and APIs, such as phenobarbital, primidone, fluorouracil, phenylbutazone, flucytosine, piroxicam, tenoxicam, and propylthiouracil. In addition, the company engages in enterprise management; technical services; goods and technology import and export; chemical wholesale; pharmaceutical retail; medical devices equipment sales; provision of cosmetics and skincare products; and investment activities. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is headquartered in Nantong, China.
Visit company website
5 years, 5 months ago
Nantong Jinghua Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 7.1% above its 200 day moving average.
From a valuation standpoint, the stock is 67.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Nantong Jinghua Pharmaceutical Co., Ltd's total revenue rose by 46.2% to $318M since the same quarter in the previous year.
Its net income has increased by 98.9% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 1256.4% to $80M since the same quarter in the previous year.
Based on the above factors, Nantong Jinghua Pharmaceutical Co., Ltd gets an overall score of 5/5.